Media stories about Galapagos (NASDAQ:GLPG) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galapagos earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8487776133527 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages recently issued reports on GLPG. Stifel Nicolaus upped their price target on shares of Galapagos from $101.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, September 15th. Morgan Stanley reiterated an “overweight” rating and issued a $92.00 price target on shares of Galapagos in a research note on Thursday, August 10th. Cowen reiterated a “buy” rating on shares of Galapagos in a research note on Thursday, August 10th. BidaskClub upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Nomura upped their price target on shares of Galapagos from $108.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $111.00.
Galapagos (NASDAQ GLPG) opened at $85.44 on Wednesday. Galapagos has a 52-week low of $57.92 and a 52-week high of $104.12.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.